{"filings":[{"id":501156,"accession_number":"0001437749-26-017637","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2026-05-18T20:58:36+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CervoMed reports Q1 2026 net loss of $8.0M; cash runway only into Sept 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $8.0M vs $4.9M YoY; no grant revenue vs $1.9M prior year.","Cash, cash equivalents and marketable securities $12.9M as of March 31, 2026, down from $20.9M at Dec 31, 2025.","Cash runway expected to fund operations into September 2026.","Plans to initiate Phase 3 DLB trial in H2 2026, subject to financing.","Presented new MRI and biomarker data at AAN 2026 and AD/PD 2026 supporting neflamapimod."],"consensus_eps_estimate":-0.7956,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90943,"accession_number":"0001437749-26-013037","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CervoMed: neflamapimod increases basal forebrain volume in DLB Phase 2b MRI analysis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At week 16, right BF volume increased 3.5% with neflamapimod vs -4.2% with placebo (p=0.028).","Right BF to DMN functional connectivity improved 46% during 32-week extension (p=0.014).","Improvement in functional connectivity correlated with CDR-SB reduction (p=0.027, r²=0.43).","Company plans to start Phase 3 trial in DLB later this year, subject to financing.","Data presented at 2026 AAN Annual Meeting by Amsterdam UMC; blinded analysis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90942,"accession_number":"0001437749-26-011597","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CervoMed presents neflamapimod Phase 3 design and MRI data at LBD Annual Meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New MRI analyses from Phase 2b RewinD-LB trial show neflamapimod may reduce basal forebrain atrophy in DLB.","Global regulatory alignment achieved; Phase 3 trial design finalized.","Plasma GFAP biomarker correlates with cognitive decline and is responsive to neflamapimod treatment.","Additional MRI data to be presented at AAN Annual Meeting on April 22, 2026.","No approved treatments for DLB in US or EU; neflamapimod aims to be first."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100806,"accession_number":"0001437749-26-009388","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CervoMed makes updated corporate presentation available on website; no new material disclosures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation posted at www.cervomed.com under Investors – Events and Presentations.","Presentation covers business, clinical studies, development plans, and financial position.","No specific new data, guidance changes, or material events disclosed in the filing.","Company undertakes no duty to update the presentation except as required by law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100805,"accession_number":"0001437749-26-009081","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CervoMed Phase 2b DLB data show greater benefit in patients without AD co-pathology","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At pTau181 <21 pg/mL, neflamapimod showed CDR-SB improvement of -1.11 vs placebo (p=0.005) in within-participant analysis.","PK/PD analyses identified therapeutic trough concentration threshold of 4 ng/mL; DP Batch B achieved this in 75% of patients vs 50% for Batch A.","Planned Phase 3 trial will use pTau181 <21 pg/mL enrichment, expecting 80-90% of patients without AD co-pathology.","Data presented March 21, 2026 at AD/PD 2026 Conference in Copenhagen, Denmark."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100804,"accession_number":"0001437749-26-008611","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CervoMed Q4/FY2025 net loss widens to $27M; cash runway ~6 months; Phase 3 DLB trial pending financing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2025 net loss $27.0M vs $16.2M; cash $20.9M (down from $38.9M), sufficient for ~6 months.","FDA alignment obtained for planned Phase 3 DLB trial; initiation in H2 2026 subject to funding.","Selected 50mg TID neflamapimod dose for Phase 3; additional data to be presented at AD/PD 2026.","Topline data expected H2 2026 from Phase 2a RAS and nfvPPA trials; ALS trial start by YE 2026.","Grant revenue fell to $4.0M from $9.7M due to RewinD-LB completion; R&D spend rose to $21.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100803,"accession_number":"0001437749-26-006911","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CervoMed selects 50mg TID neflamapimod dose for Phase 3 DLB trial after Phase 1 PK study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 healthy volunteer study completed evaluating PK of a new stable crystal form of neflamapimod.","Selected 50mg three times per day (TID) as dosing regimen for planned Phase 3 dementia with Lewy bodies trial.","PK profile of 40mg stable crystal form largely overlaps with therapeutically active DP Batch B from Phase 2b extension.","Dose increased to 50mg TID to ensure plasma drug concentrations match those of the active batch.","New controlled manufacturing process produces only stable crystal form, mitigating prior polymorph conversion issues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100802,"accession_number":"0001437749-26-004555","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CervoMed's neflamapimod selected for UK EXPERTS-ALS platform for ALS trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Neflamapimod will be evaluated in EXPERTS-ALS, funded by UK NIHR and motor neuron disease charities, costs covered externally.","Initial phase: ~35 ALS patients for 18-24 weeks measuring neurofilament light chain (NfL) biomarker; potential expansion to 80.","First patient with ALS expected to be dosed by end of 2026; trial sponsored by Sheffield Teaching Hospitals NHS Foundation Trust.","CervoMed maintains primary focus on dementia with Lewy bodies (DLB); Phase 3 in DLB planned to start later in 2026.","Inclusion based on neflamapimod's p38 inhibition, ability to cross BBB, and positive prior clinical safety/biomarker data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100801,"accession_number":"0001437749-26-000883","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CervoMed posts investor presentation on website; no material updates in 8-K","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation available at www.cervomed.com under 'Investors – Events and Presentations'.","Company may use the presentation in conferences and meetings with non-material modifications.","No financial or clinical data from the presentation is disclosed in this filing.","Filing emphasizes presentation is summary information subject to risk factors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117108,"accession_number":"0001437749-25-037025","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Neflamapimod slows DLB progression in Phase 2b; 89% worsening reduction in key subgroup","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint CDR-SB mean change 52% lower with DP Batch B vs control; 82% lower in patients without AD co-pathology.","Within-patient comparison vs placebo: 1.12 point improvement on CDR-SB (p=0.005); ADCS-CGIC improved (p=0.004).","Risk of clinical progression reduced 75%; median time to progression extended from 16 weeks to 1.5 years.","Plasma GFAP reduced median -16.0 pg/mL (p<0.0001); reduction correlated with clinical treatment response.","Company planning Phase 3 registrational trial in patients with DLB starting H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117107,"accession_number":"0001437749-25-034095","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CervoMed reports Q3 2025 net loss $7.7M; FDA aligned on Phase 3 trial design for neflamapimod in DLB","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.7M for Q3 2025 vs $4.8M in Q3 2024; cash $27.3M at Sept 30, 2025.","FDA alignment on design of planned Phase 3 trial of neflamapimod for dementia with Lewy bodies; global pivotal trial initiation targeted H2 2026.","Phase 2b RewinD-LB 32-week data showed 64% risk reduction in clinically significant worsening on CDR-SB (p<0.001) in DLB patients with low AD co-pathology.","R&D expenses $6.0M (up $0.9M YoY) primarily due to increased personnel and CMC activities; G&A $2.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":3997784.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117106,"accession_number":"0001437749-25-032869","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CervoMed gets FDA alignment on Phase 3 trial design for neflamapimod in DLB","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA aligned on primary endpoint (CDR-SB), patient enrichment strategy, and trial design for ~300 DLB patients.","Enrollment to exclude Alzheimer’s co-pathology via brain imaging, CSF, and plasma ptau181 ≥ 21.0 pg/mL cutoff.","Phase 3 trial planned to start in H2 2026; 32-week double-blind period followed by 48-week open-label extension.","No approved therapies for DLB in US or EU; neflamapimod targets cognitive and functional decline.","Company expects additional global regulatory feedback in coming months; detailed design early 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117105,"accession_number":"0001437749-25-032184","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"CervoMed appoints former McKinsey Senior Partner David Quigley to Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Quigley appointed to board effective Oct 27, 2025; board expanded from 7 to 8 members.","Quigley was McKinsey Senior Partner (2010-2025) leading Private Capital and Life Sciences practices.","Granted option to buy 16,200 shares at $7.02, vesting in 36 equal monthly installments.","Company expects FDA feedback on Phase 3 trial design for neflamapimod in DLB in Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117104,"accession_number":"0001437749-25-031523","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CervoMed posts investor presentation on website; no material new information disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation made available at www.cervomed.com under Investors – Events and Presentations.","Contains summary information on business, clinical studies, and development plans.","Company undertakes no duty to update the presentation except as required by law.","No specific financial results, guidance, or material events provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117103,"accession_number":"0001437749-25-030719","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2025-10-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CervoMed new Phase 2b data: neflamapimod improves CDR-SB in DLB subgroup, reduces GFAP biomarker","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In DLB patients with low AD co-pathology (ptau181<21 pg/mL), neflamapimod showed significant improvement on CDR-SB (p=0.005) in within-subject comparison to placebo.","Neflamapimod reduced the risk of clinically meaningful progression by 75% vs placebo over 16 weeks (p<0.001).","Plasma GFAP levels decreased by median -23.1 pg/mL on neflamapimod vs +5.8 on placebo (p=0.016); GFAP change correlated with CDR-SB.","FDA feedback on Phase 3 trial design expected in Q4 2025.","Two drug capsule batches were used; only the newer batch (NFMD/B) achieved target plasma concentrations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133558,"accession_number":"0001437749-25-025814","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CervoMed reports Q2 loss $6.3M; neflamapimod shows 54% risk reduction in DLB extension phase","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.3M for Q2 2025 vs $2.3M loss a year ago; cash $33.5M as of June 30, 2025.","Phase 2b RewinD-LB extension: neflamapimod reduced risk of clinically significant worsening by 54% (p=0.0037) on CDR-SB at 32 weeks.","In patients with minimal AD co-pathology (ptau181<2.2), risk reduction improved to 64% (p=0.0001).","Significant decrease in plasma GFAP biomarker: -18.4 pg/mL from baseline in active group vs +1.1 pg/mL increase in placebo at Week 16.","Plans to meet FDA in Q4 2025 to align on Phase 3 trial design; Phase 3 initiation mid-2026 subject to funding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":3675215.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133557,"accession_number":"0001437749-25-024847","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CervoMed posts investor presentation on website; no new material information disclosed.","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation posted on August 5, 2025 under 'Investors – Events and Presentations' at www.cervomed.com.","No new financial results, clinical data, or guidance were provided in the 8-K.","The company may use the presentation in meetings with investors and analysts without material modifications.","No specific numbers, names, or events were mentioned in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133556,"accession_number":"0001437749-25-023646","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CervoMed reports neflamapimod 54% risk reduction on CDR-SB at Week 32 in DLB trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At Week 32, neflamapimod showed 54% risk reduction in >=1.5-point CDR-SB worsening vs control (p=0.0037); 64% in ptau181<2.2 patients (p=0.0001).","Significant reduction in plasma GFAP biomarker: mean change -18.4 pg/mL (p<0.0001) for New Capsules over 32 weeks.","Plans to initiate Phase 3 trial and meet with FDA in Q4 2025 to align on trial design.","New Capsules achieved target plasma exposures; Old Capsules did not; similar safety profiles.","Trial funded by $21.3M NIH/NIA grant; 43 sites across US, UK, Netherlands."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150232,"accession_number":"0001437749-25-021278","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"CervoMed stockholders elect seven directors and approve 2025 equity plan at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected; John Alam received 3,923,241 votes for, 21,554 withheld.","Ratification of RSM US LLP as auditor approved: 5,571,505 for, 25,008 against, 13,724 abstain.","Advisory vote on 2024 executive compensation approved with 3,891,229 for, 33,195 against, 20,371 abstain.","CervoMed 2025 Equity Incentive Plan approved: 3,798,568 for, 137,758 against, 8,469 abstain.","Approximately 5.61 million shares voted, representing 64.5% of outstanding shares; all proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150231,"accession_number":"0001437749-25-017613","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CervoMed posts investor presentation on website, no material new data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation made available on www.cervomed.com under Investors – Events and Presentations.","Presentation may be used in conferences and meetings; no financial or clinical updates provided.","Company undertakes no duty to update the presentation except as required by law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150230,"accession_number":"0001437749-25-016131","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"CervoMed posts Q1 net loss $4.9M, secures $50M ATM facility; reports positive Phase 2b DLB results","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered $50M at-the-market offering agreement with Leerink Partners; 3% commission on sales.","Cash and marketable securities $35.2M at March 31, 2025, down from $38.9M at Dec 31, 2024; runway into mid-2026.","Net loss $4.9M for Q1 2025 compared to $2.5M in Q1 2024, driven by higher R&D costs for neflamapimod.","Sixteen-week extension data from RewinD-LB Phase 2b showed CDR-SB improvement (p<0.001 vs old capsules, p=0.003 vs placebo); Phase 3 planned in mid-2026.","Initiating Phase 2a trials in primary progressive aphasia (mid-2025) and ischemic stroke recovery (recently started)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150229,"accession_number":"0001437749-25-012337","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["1.01","1.02","5.02","9.01"],"status":"ready","headline":"CervoMed appoints EVP Clinical Development and EVP Regulatory; COO Cobuzzi to depart July 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kelly Blackburn promoted to EVP Clinical Development (previously SVP), effective April 16, 2025; base salary $448,360, target bonus 35%.","Mark De Rosch appointed EVP Regulatory and Government Affairs and Program Management, effective May 1, 2025; base salary $465,000, target bonus 35%.","Robert Cobuzzi, COO, to depart July 1, 2025; not standing for re-election; receives lump-sum $479,723 plus pro-rated bonus and COBRA.","Agreements include severance, non-compete, non-solicitation, and change-of-control provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150228,"accession_number":"0001437749-25-011178","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CervoMed reports positive Phase 2b extension data for neflamapimod in DLB","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Neflamapimod slowed clinical progression on CDR-SB vs old capsules (p<0.001) and vs placebo (p=0.003) over 16 weeks.","Mean CDR-SB improvement of 0.73 points with new capsules vs old; 40% relative reduction in clinically meaningful worsening.","Falls incidence reduced to 4% with new capsules vs 15.2% with old (p=0.025) in patients without AD co-pathology.","Improvement also seen on ADCS-CGIC (p=0.035 vs old capsules) and cognitive/fluctuation endpoints.","Company expects to complete full 32-week extension and engage FDA for Phase 3 plans later in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169237,"accession_number":"0001437749-25-008249","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["2.02","9.01","7.01"],"status":"ready","headline":"CervoMed reports Q4/FY2024 results; positive Phase 2b extension data for neflamapimod in DLB","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $38.9M at Dec 31, 2024 (up from $7.8M); funded into mid-2026.","Net loss $16.3M for FY2024 vs $2.2M in 2023 (2023 included noncash gain).","Positive 16-week extension results: improvement on CDR-SB (p<0.001 vs old capsules; p=0.003 vs placebo).","Plan to initiate Phase 3 trial in mid-2026 after regulatory meetings.","Added senior VPs Claudia Ordonez (Medical Science) and Mark De Rosch (Regulatory)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169236,"accession_number":"0001437749-25-007027","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"CervoMed posts updated investor presentation on its website","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation posted under 'Investors – Events and Presentations' on www.cervomed.com.","Covers business, clinical studies, development plans, and financial position.","Company does not undertake to update the information except as required by law.","No specific financial or clinical results disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169235,"accession_number":"0001437749-25-006832","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CervoMed announces positive Phase 2b extension results for neflamapimod in DLB","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New capsule batch yielded higher plasma levels; CDR-SB improved vs old capsules (p<0.001) and vs placebo (p=0.003).","CGIC score improved with new capsules vs old (4.02 vs 4.46, p=0.035); within-subject placebo comparison also significant (p=0.035).","Fall incidence lower with new capsules (7.4%) vs old (14.5%) and vs placebo (18.8%, p=0.04); in ptau181 <2.2 subgroup: 4.0% vs 19.7% (p=0.007).","149 patients entered extension; 94 received new capsules; completion rates 87.3% (old) and 91.5% (new); no new safety signals.","Company plans to complete full 32-week extension and discuss Phase 3 plans with regulators later this year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169234,"accession_number":"0001437749-25-002329","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2025-01-31T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CervoMed reports no difference between neflamapimod and placebo in DLB trial; OLE data expected Q1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No discernible differences between neflamapimod 40mg TID and placebo during 16-week double-blind phase of RewinD-LB trial.","Measured trough plasma concentrations similar to 40mg BID in prior Alzheimer's study, lower than targeted.","Retrospective analysis suggests lower bioavailability related to age of drug batch used in double-blind phase.","PK data from food-effect study and within-subject comparison (13 participants) indicate newer capsules achieved target concentrations.","Topline data from first 16 weeks of open-label extension (OLE) phase expected in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186279,"accession_number":"0001437749-24-037053","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CervoMed Phase 2b DLB trial fails primary and secondary endpoints; neflamapimod no better than placebo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Neflamapimod did not demonstrate statistically significant effects vs placebo on CDR-SB, TUG, NTD, or CGIC at 16 weeks.","Target plasma drug concentrations were not achieved during double-blind phase, likely negatively impacting results.","Favorable safety/tolerability profile with no new safety signal identified.","Company pausing all Phase 3 preparations for early-stage DLB until full analysis complete.","Full double-blind data expected January 2025; open-label first 16 weeks data expected late Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186278,"accession_number":"0001437749-24-036505","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2024-12-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CervoMed posts corporate presentation on website for investor meetings","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation available at www.cervomed.com under 'Investors – Events and Presentations'.","Company may use the presentation with non-material modifications at conferences and investor meetings.","No specific financial results or clinical data updates disclosed in the 8-K.","Company undertakes no duty to update the presentation except as required by law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186277,"accession_number":"0001437749-24-036335","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2024-11-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CervoMed's neflamapimod gets FDA Orphan Drug Designation for frontotemporal dementia","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Orphan Drug Designation for neflamapimod to treat frontotemporal dementia (FTD).","Designation recognizes scientific rationale; FTD currently has no approved treatment options.","CervoMed in discussions with clinical thought leaders to design a proof-of-principle FTD study.","Company on track to report topline data from RewinD-LB Phase 2b trial in DLB in December 2024.","Benefits include development assistance, tax credits, fee exemptions, and 7-year post-approval exclusivity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186276,"accession_number":"0001437749-24-034889","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"CervoMed reports Q3 2024 net loss $4.8M; cash $46.7M; RewinD-LB data due Dec 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.8M in Q3 2024 vs net income $2.2M in Q3 2023; R&D expenses rose to $5.1M from $1.8M.","Cash, cash equivalents and marketable securities $46.7M at Sep 30, 2024 (vs $50.9M at Jun 30); cash runway through 2025.","RewinD-LB Phase 2b top-line data expected Dec 2024; last patient visit Oct 2024. Plan Phase 3 mid-2025 and Phase 2a for stroke Q1 2025.","Awarded Prix Galien USA 2024 Best Startup on Nov 8, 2024, recognizing innovation in DLB treatment development.","Appointed Claudia Ordonez (SVP Medical) and Mark De Rosch (SVP Regulatory); granted options for 56,959 shares at $12.53."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":7575972.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186275,"accession_number":"0001437749-24-033168","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CervoMed reports Phase 2a biomarker data for neflamapimod in DLB; RewinD-LB topline due Dec 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plasma GFAP significantly reduced by neflamapimod (p=0.015 vs placebo); reductions linked to clinical improvement.","RewinD-LB Phase 2b trial fully enrolled; topline data expected December 2024.","Study has >95% statistical power for primary endpoint (CDR-SB) after excluding patients with tau pathology.","DLB affects >1.4M patients in U.S. and EU with no approved treatment, per CervoMed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186274,"accession_number":"0001437749-24-032540","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CervoMed to present RewinD-LB Phase 2b data at ILBDC Jan 2025; topline due Dec 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Oral presentation of detailed safety/efficacy results from neflamapimod Phase 2b in DLB at ILBDC on Jan 31, 2025.","Topline results from RewinD-LB Phase 2b trial expected to be disclosed in December 2024.","CEO expresses confidence in trial design to detect statistically significant and clinically meaningful difference.","Baseline patient characteristics from RewinD-LB to be presented at CTAD conference.","No approved therapies for DLB; neflamapimod aims to address this unmet need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186273,"accession_number":"0001437749-24-031300","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CervoMed completes last patient visit in Phase 2b DLB trial; topline data expected Dec 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Last patient last visit completed in Phase 2b RewinD-LB trial evaluating neflamapimod in early-stage DLB.","96% of patients completed the 16-week double-blind placebo-controlled portion; 98% continued into open-label extension.","DSMB concluded study may proceed without modification after pre-specified safety data review.","Company on track to report topline efficacy and safety data in December 2024.","Late-breaking oral presentations on plasma biomarker data planned at upcoming CTAD conference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186272,"accession_number":"0001437749-24-030613","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"CervoMed terminates $20M ATM equity facility with BTIG; no shares sold","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Terminated At-The-Market Sales Agreement with BTIG, effective October 11, 2024.","No shares were ever issued under the $20M facility; no termination penalties apply.","Company notified BTIG on October 1, 2024 of the termination.","Originally entered into July 22, 2022; no proceeds or dilution occurred."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186271,"accession_number":"0001437749-24-030299","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CervoMed to present neflamapimod biomarker and baseline data at CTAD; topline RewinD-LB due Dec 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two late-breaking oral presentations at CTAD in Madrid (Oct 29 – Nov 1) on neflamapimod for DLB.","Plasma biomarker data from AscenD-LB Phase 2a study will be presented November 1.","Baseline data from RewinD-LB Phase 2b study to be featured; CEO says increases confidence in positive outcome.","Topline data from RewinD-LB Phase 2b study expected in December 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202902,"accession_number":"0001437749-24-027012","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"CervoMed reports Q2 2024 net loss $2.3M, cash $50.9M; DLB trial enrolled, topline Dec 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.3M in Q2 2024 vs $1.4M in Q2 2023; operating loss $3.0M vs $1.2M.","Cash, equivalents and marketable securities $50.9M at June 30, 2024, up from $7.8M at Dec 31, 2023.","Completed enrollment in Phase 2b RewinD-LB trial (neflamapimod for early-stage DLB) in June 2024; topline data expected Dec 2024.","Private placement in April 2024 raised $50M upfront, with potential total proceeds up to $149.4M.","NIA grant revenue $5.6M for H1 2024 vs $3.1M for H1 2023; cash runway extended through 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":5636221.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202901,"accession_number":"0001437749-24-024329","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CervoMed presents Phase 2a biomarker data at AAIC; neflamapimod reduces plasma GFAP in early DLB","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Poster at AAIC 2024: baseline plasma GFAP highly correlated with CDR-SB dementia severity in DLB patients.","In early-stage DLB (no AD co-pathology), neflamapimod reduced plasma GFAP by mean 10.6 pg/mL vs placebo increase of 14.1 pg/mL (p=0.04).","Reduction in GFAP correlated with improvement in CDR-SB in neflamapimod-treated early DLB patients (r=0.54, p=0.04).","Fully enrolled RewinD-LB Phase 2b trial to report topline primary efficacy results in December 2024.","Management to participate in fireside chat at Canaccord Genuity 44th Annual Growth Conference on August 13, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202900,"accession_number":"0001437749-24-023240","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CervoMed announces July 23 virtual KOL event on neflamapimod for DLB; no new data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Event focused on neflamapimod for dementia with Lewy bodies.","Presentation available on company website; no material results in 8-K.","Company may reuse presentation in future investor meetings.","No forward-looking statements or financial guidance updated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202899,"accession_number":"0001437749-24-022658","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2b RewinD-LB trial of neflamapimod for dementia with Lewy bodies fully enrolled; topline data expected December 2024.","KOL event on July 23, 2024 features John-Paul Taylor (Newcastle Univ.) and Ralph A. Nixon (NYU Grossman School of Medicine).","Agenda includes DLB disease state, neflamapimod mechanism, plasma phosphorylated tau patient selection, and trial design.","Live Q&A session moderated by CervoMed CEO John Alam following the formal presentations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219101,"accession_number":"0001437749-24-020335","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"CervoMed completes enrollment in Phase 2b neflamapimod trial for DLB; topline data due Dec 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB) fully enrolled.","Topline data expected in December 2024 (16-week double-blind placebo-controlled period).","Trial targets up to 160 patients; excludes AD co-pathology via plasma ptau181 screen (two-thirds eligible).","Primary endpoint: Clinical Dementia Rating Sum of Boxes; funded by $21M NIH/NIA grant.","43 sites (32 US, 8 UK, 3 Netherlands) all initiated; open-label extension for 32 additional weeks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219100,"accession_number":"0001437749-24-017648","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["1.01","5.02","1.02","8.01","9.01"],"status":"ready","headline":"CervoMed names William Elder as CFO; William Tanner departs to consulting role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["William Elder appointed CFO effective June 1, 2024, succeeding William Tanner; Elder continues as General Counsel and Corporate Secretary.","Outgoing CFO William Tanner to serve as consultant through Dec 2025; receives $162,000 severance plus prorated bonus and extended stock option vesting.","Elder's compensation: base salary $429,000, target bonus 35% of base; severance includes 9 months salary on non-cause termination.","Company expects RewinD-LB Phase 2b enrollment completion in Q2 2024, topline efficacy results in Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219099,"accession_number":"0001437749-24-017132","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CervoMed reports Q1 net income $2.5M; DLB trial enrollment on track for Q2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $6.4M as of March 31; plus $50M upfront from private placement closed April 1 provides runway through end 2025.","RewinD-LB Phase 2b enrollment on track to complete in Q2 2024; topline data expected Q4 2024.","Net income $2.5M in Q1 vs net loss $0.5M in Q1 2023; operating loss widened to $2.6M from $1.4M.","Grant revenue from NIA $2.3M in Q1 vs $1.4M; R&D expenses increased to $2.8M.","Up to $149.4M private placement with leading healthcare investors; $50M gross upfront."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":2347250.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219098,"accession_number":"0001437749-24-012761","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2024-04-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CervoMed reports 8,253,741 shares outstanding as of April 22, 2024","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Share count disclosed as 8,253,741 shares of common stock outstanding as of April 22, 2024.","No other material updates or events reported in the filing.","The corporate presentation made available on the company's website contains no new clinical or financial data disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219097,"accession_number":"0001437749-24-011212","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2024-04-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CervoMed posts 2023 net loss of $2.2M; secures $50M private placement; Phase 2b DLB trial on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.2M for 2023; cash $7.8M as of Dec 31, 2023; R&D spending increased to $8.4M.","Private placement of $50M upfront (up to $149.4M with warrants) led by RA Capital; expected to fund through end of 2025.","RewinD-LB Phase 2b enrollment on track to complete Q2 2024; topline data expected Q4 2024.","Appointed Joshua Boger, founder of Vertex Pharmaceuticals, as non-executive Chair of the Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":2347250.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219096,"accession_number":"0001437749-24-010998","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2024-04-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CervoMed posts corporate presentation on website; no material new disclosures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company made a corporate presentation available on its website under 'Investors – Events and Presentations'.","Presentation may be used in meetings with investors and analysts; no modifications to the filing content.","No specific financial, clinical, or operational updates provided in this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238983,"accession_number":"0001437749-24-009697","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"CervoMed secures $50M upfront private placement; warrants could add $99.4M; funds Phase 2b DLB trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$50M upfront; up to ~$149.4M if Series A warrants ($39.24/share, 100% premium) fully exercised.","Unit price $19.745; includes pre-funded warrants ($0.001 strike) and Series A warrants expiring Apr 2027 or post positive Phase 2b data.","Financing led by RA Capital Management with Armistice, Special Situations, Soleus; Morgan Stanley and Canaccord placement agents.","Net proceeds to fund neflamapimod R&D for dementia with Lewy bodies; expected cash runway through end of 2025.","Closing expected April 1, 2024; resale registration statement to be filed within 60 days after close."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238982,"accession_number":"0001437749-24-008315","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["5.08","9.01"],"status":"ready","headline":"CervoMed sets June 14, 2024 annual meeting; proposal deadline April 1","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting of stockholders set for June 14, 2024; will be held virtually.","Stockholder proposals for inclusion in proxy must be submitted by April 1, 2024.","Company did not hold an annual meeting in 2023.","Additional details will be provided in definitive proxy statement filed with SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":238981,"accession_number":"0001437749-24-006546","cik":1053691,"company_name":"CervoMed Inc.","ticker":"CRVO","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CervoMed reports Phase 2a biomarker data: neflamapimod reduces GFAP, correlates with clinical outcomes in DLB","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In pure DLB patients, neflamapimod reduced GFAP by mean 10.6 pg/mL vs 14.1 increase with placebo (p=0.04).","GFAP reduction correlated with improvement on CDR-SB (r=0.542, p=0.036) in neflamapimod-treated pure DLB patients.","Preclinical data from UCL shows neflamapimod enhances axonal transport in tauopathy mouse model of FTD.","CEO states data support clinical efficacy in DLB and rationale for evaluating neflamapimod in frontotemporal dementia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":28146503.816393442,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}